Monopar Therapeutics, trading under the ticker MNPR on NASDAQ, has been catching some attention with its recent positive news. However, a deeper dive into its stock technicals suggests a more nuanced picture. The company, part of the biotechnology sector, reported a loss of $9.5 million from continuing operations, which raises questions about its financial health. While the stock's 50-day moving average sits at $5.46, significantly above its 200-day moving average of $3.85, indicating some recent upward momentum, investors should be cautious. The gap between these averages could suggest volatility, and it's crucial to consider these factors alongside the broader market dynamics before making any investment decisions. Biotechnology can be an exciting field, and Monopar Therapeutics is a company worth examining closely to understand its potential. Despite recent market fluctuations, there are reasons to remain optimistic about its recovery prospects. While Monopar's recent stock movements have diverged from broader market trends, it's important to note that the company's fundamental indicators suggest potential long-term challenges for retail investors. Currently, the stock is seeing higher-than-average trading activity, which could signal increased investor interest or volatility.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Monopar Therapeutics. In general, sophisticated investors focus on analyzing Monopar Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Monopar Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Monopar Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Monopar Therapeutics, many experienced traders also check how macroeconomic factors affect Monopar Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
How important is Monopar Therapeutics's Liquidity
Monopar Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Monopar Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Monopar Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Monopar Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Monopar Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Monopar Therapeutics's total debt and its cash.
Monopar Therapeutics Gross Profit
Monopar Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Monopar Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Monopar Therapeutics Gross Profit growth over the last 10 years. Please check Monopar Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at Monopar Therapeutics Semi Variance
Monopar Therapeutics has current Semi Variance of 69.44. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.
Semi-variance is the square of semi-deviation.
Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.
Semi Variance | = | SUM(RET DEV)2N(ZERO) |
| = | 69.44 |
| SUM | = | Summation notation |
| RET DEV | = | Actual return deviation over selected period |
| N(ZERO) | = | Number of points with returns less than zero |
Let's now compare Monopar Therapeutics Semi Variance to its closest peers:
| MNPR | 69.4362367462415 |
| ANEB | 48.07 |
| ACRV | 13.97 |
| PMVP | 5.05 |
| MOLN | 30.2 |
Not all that glitters is gold, and Monopar Therapeutics (NASDAQ: MNPR) might be a case in point. While recent headlines have painted a rosy picture, a deeper dive into the stock's technicals suggests caution. The company's operating income shows a significant loss of 8.8 million, which could be a red flag for potential investors. Despite a strong current ratio of 7.61X indicating good short-term financial health, the stock's price action indicator at -2.64 suggests bearish momentum. With a beta of 1.26, Monopar's stock is more volatile than the market, which could lead to unpredictable swings, making it essential for investors to weigh the risks carefully..
Monopar Therapeutics latest fall is misleading
Monopar Therapeutics has recently experienced a drop in its stock price, which might raise concerns for some investors. However, examining its risk-adjusted performance, currently at 0.1, reveals that the company is managing its risks fairly well despite market ups and downs. While there's a chance the stock could fall further, this performance metric offers a hopeful sign that the company might stabilize and bounce back. Investors should consider this perspective before reacting hastily to recent price changes.
Monopar Therapeutics is experiencing significant return volatility over the chosen period. Understanding these volatility trends can help investors make informed decisions.
By using volatility indicators, traders can assess Monopar's stock risk relative to market swings, whether in rising or falling markets. High volatility in bear markets can impact Monopar's stock price, often prompting investors to adjust their portfolios as prices drop.While Monopar Therapeutics has recently been in the spotlight, it's essential to approach its stock with a degree of caution. Despite the buzz, the stock's valuation market value of
16.21 suggests a disconnect from its real value of 11.42, indicating that the current excitement may be inflating its worth. Furthermore, with only one analyst buy and two strong buys, the enthusiasm isn't as widespread as one might hope for a robust investment. While the analyst consensus is a strong buy, potential investors should weigh these factors carefully and consider the possible downside price of 0.16 before making any decisions..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Monopar Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com